Immunogenomics of Disease : Accelerating to Patient Benefit 2017

Immunogenomics of Disease : Accelerating to Patient Benefit is organized by Wellcome Genome Campus and would be held during Feb 6 - 8, 2017 at Wellcome Genome Campus Conference Centre, Hinxton, England, United Kingdom.

This new conference aims to bring together scientists working in the fields of molecular immunology, functional genomics and immune-mediated disease genetics to expedite the journey from genetic association to mechanistic understanding and patient benefit through new insights into disease and novel therapeutics.

Next generation sequencing has accelerated the discovery of highly penetrant causal variants in diverse primary immune deficiencies, providing insight into the non-redundant functions of the affected genes and pathways in human immunity. In parallel, the application of GWAS has been arguably most successful in immune-related traits, such that together we now have evidence of the role of genetic variation in susceptibility to various immune diseases across the prevalence spectrum. To accelerate the translation of these discoveries into the clinic, we urgently need to improve our understanding of the molecular consequences of disease-associated variants, immunological processes and drug target discovery.

This meeting will focus on recent successful stories in immune-mediated disease gene-mapping, causal variant identification in common and rare immune diseases, and efforts to understand the cellular consequences of these variants on the innate and adaptive immune system. We will highlight technological developments that promise to deliver further insight into the biology of the immune system in both health and disease, such as single cell sequencing, metagenomic sequencing and genome editing.

Topics will include :
• Autoimmunity and autoinflammation
• Primary immune deficiencies
• Immunology and the microbiome
• Genomic diversity of immune cells
• Immune regulation and homeostasis

Speakers : John Todd (University of Cambridge, UK), Mike Lenardo (National Institutes of Health, USA), Ivona Aksentijevich (National Institutes of Health, USA), Mary Carrington (National Cancer Institute Center for Cancer Research, USA), Yanick Crow (Imagine Institute, France), Lars Fugger (University of Oxford, UK) Michel Georges (University of Liege, Belgium), Claire Harris (Cardiff University, UK), Eric Meffre (Yale University, USA), Anjana Rao (La Jolla Institute for Allergy and Immunology, USA), Soumya Raychaudhuri (Harvard Medical School, USA), Sarah Teichmann (Wellcome Trust Sanger Institute, UK), Gosia Trynka (Wellcome Trust Sanger Institute, UK), Holm Uhlig (University of Oxford, UK), Cisca Wijmenga (University of Groningen, The Netherlands).